Abstract
We would like to thank Dr. Dai and colleagues for their insightful comments on our article (1,2). They suggested that the increased risk of serious infections observed in vedolizumab-treated patients with Crohn's disease (CD), compared with those treated with anti-tumor necrosis factor agents (anti-TNFs), had not been seen in previous studies. Although it is true that some studies have not identified significant differences in treatment-associated risks, most studies demonstrate non-statistically significant increased risks of infections in patients with CD. We caution readers against concluding that there is no association based solely on P-values >0.0
Original language | English |
---|---|
Journal | The American Journal of Gastroenterology |
Volume | 120 |
Issue number | 1 |
Pages (from-to) | 260-261 |
Number of pages | 2 |
ISSN | 0002-9270 |
DOIs | |
Publication status | Published - 2025 |